IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Status:
Active, not recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show that abiraterone acetate plus prednisone added to the
current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific
antigen (PSA) and prolongs the time until it is evident that the cancer has grown.
Additionally, safety information about abiraterone acetate in combination with prednisone
will be collected. This will include looking at what side effects occur, how often they
occur, and for how long they last.